Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Kestra Medical Technologies (Nasdaq: KMTS) reported FY ended Apr 30, 2026 results. Q4 revenue rose 66% to $28.6M and gross margin to 54.8%. FY26 revenue increased 59% to $95.1M with gross margin 51.4%. It guided FY27 revenue to $137M (+44%).
How this was made
The 30-second read
Why it matters
Traders can update forward revenue and margin expectations using the disclosed FY26 performance and the explicit FY27 revenue target, while monitoring whether commercialization spend continues to pressure GAAP losses.
Market read
FY26 revenue growth of 59% and gross margin expansion to 51.4%, plus FY27 revenue guidance of $137M (+44%), are the core decision inputs for KMTS positioning.
What to watch
Adjusted operating expense and adjusted EBITDA losses widened, implying profitability progress may be slower than revenue growth suggests; prescription growth and in-network mix improvements may not fully translate into durable margins.
Background
Kestra Medical Technologies reported fourth quarter and full fiscal year results for the year ended April 30, 2026, and provided FY27 revenue guidance.
Ticker impact
Kestra (KMTS) reported FY26 revenue of $95.1M (+59% YoY), gross margin expansion to 51.4%, and issued FY27 revenue guidance of $137M (+44%).
Likely positive bias for KMTS as guidance and gross margin expansion support higher forward estimates, though GAAP losses and rising operating expenses may temper the reaction.
The article provides multiple decision-relevant datapoints: FY26 revenue and gross margin, prescription growth for the ASSURE system, and explicit FY27 revenue guidance. It does not provide consensus context or valuation, so magnitude of price impact is uncertain.
Market effects
Supports read-through for wearable cardiac monitoring and digital health device adoption, especially if ASSURE prescription growth continues.
Primarily US-listed small-cap medtech sentiment; limited direct regional spillover beyond investor focus on US healthcare growth.
Modest global relevance, as the disclosure is company-specific and does not indicate international regulatory or reimbursement changes.
Counterpoint
GAAP operating expenses and GAAP net loss remain large and increased in FY26, so the market may discount the margin gains if they are not sustained or if commercialization costs keep rising.
Key entities
- companyKestra Medical Technologies, Ltd.
Nasdaq-listed wearable medical device and digital healthcare company reporting FY26 results and FY27 revenue guidance.
- productASSURE system
Wearable cardioverter defibrillator platform referenced via prescription and patient protection metrics.
- collaboration_partnerBiobeat Technologies
Named as a strategic collaboration partner in the CEO’s remarks.
